articleJournal of the National Comprehensive Cancer NetworkAug 1, 2017Closed access

Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology

University of California, San Francisco · Moffitt Cancer Center · +28 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

Ductal adenocarcinoma and its variants account for most pancreatic malignancies. High-quality multiphase imaging can help to preoperatively distinguish between patients eligible for resection with curative intent and those with unresectable disease. Systemic therapy is used in the neoadjuvant or adjuvant pancreatic cancer setting, as well as in the management of locally advanced unresectable and metastatic disease. Clinical trials are critical for making progress in treatment of pancreatic cancer. The NCCN Guidelines for Pancreatic Adenocarcinoma focus on diagnosis and treatment with systemic therapy, radiation therapy, and surgical resection.

Citation impact

1,028
total citations
FWCI
55.84
Percentile
100%
References
155
Citations per year

Authors

36

Topics & keywords

Keywords
  • Medicine
  • Adenocarcinoma
  • Pancreatic cancer
  • Systemic therapy
  • Oncology
  • Neoadjuvant therapy
  • Internal medicine
  • Pancreatic ductal adenocarcinoma
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.